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The aim of this paper was to investigate the presence of the urinary 90kDa N-domain ACE in a cohort of the population
from Vitoria, Brazil, to verify its association with essential hypertension since this isoform could be a possible genetic marker
of hypertension. Anthropometric, clinical, and laboratory parameters of the individuals were evaluated (n = 1150) and the blood
pressure (BP) was measured. The study population was divided according to ACE isoforms in urine as follows: ACE 65/90/190,
presence of three ACE isoforms (n = 795), ACE90+ (65/90) (n = 186), and ACE 90− (65/190) (n = 169) based on the presence (+)
or absence (−) of the 90kDa ACE isoform. The anthropometric parameters, lipid proﬁle, serum levels of uric acid, glucose, and
the systolic and diastolic BP were signiﬁcantly greater in the ACE 90+ compared with the ACE 90− and ACE 65/90/190 individuals.
We found that 98% of individuals from the ACE 90+ group and 38% from the ACE 65/90/190 group had hypertension, compared
to only 1% hypertensive individuals in the ACE 90− group. There is a high presence of the 90kDa N-domain ACE isoform (85%)
in the studied population. The percentile of normotensive subjects with three isoforms was 62%. Our ﬁndings could contribute to
the development of new eﬃcient strategy to prevent and treat hypertension to avoid the development of cardiovascular disease.
1.Introduction
Essential hypertension (EH) is a multifactorial and polygenic
disorder aﬀecting around 27% of adults worldwide [1]. It
has been considered a public health problem because of
its major contribution to the global disease burden [2].
Hypertension is an important risk factor for cardiovascular
diseases since it can lead to cardiac dysfunction and kidney
and cerebrovascular diseases [1–4]. Despite the therapeutic
agents available to treat this disease, blood pressure control
in hypertensive patients is generally poor ranging from only
5% to 58% in diﬀerent population studies [5]. Hypertension
aﬀects approximately 50 million individuals in the United
States and 1 billion individuals worldwide [5, 6]. In Brazil,
isolated studies have shown a high prevalence of the disease
in the adult population, ranging from 22 to 44%, mostly
above 25.0% [7].
Many pathophysiological factors have been implicated
in the genesis of EH [4]. The renin-angiotensin system
(RAS) accounts for the synthesis of several bioactive peptides
playing a key role in the maintenance of blood pressure as
well as ﬂuid and salt balance homeostasis. Therefore, the
RAS continues to attract the interest of many investigators
exploring the role of genetic mechanism involved in the
development of EH [8, 9]. Angiotensin converting enzyme
(ACE) is a key component of the RAS by converting the
inactive decapeptide angiotensin I (AngI) to angiotensin
II (AngII), which is a potent vasoconstrictor [10], and2 International Journal of Hypertension
by inactivating the vasodilator bradykinin [11]. ACE (EC
3.4.15.1) is a peptidyl-dipeptidase A [12] and there are two
usually described isoforms: the somatic ACE (150–190kDa)
having two active sites C and N-domains, highly bounded
to endothelial cells membrane, and the germinal ACE (90–
110kDa), found speciﬁcally in the testicles, exhibiting only
aC - d o m a i na c t i v es i t e[ 13, 14]. N-domain soluble forms of
ACE were described in human ileal ﬂuid and in human and
rats urine [15–21].
Our group has recently described the 65kDa N-domain
isoform of ACE in the urine of both normotensive and
hypertensive humans and rats, and the 90kDa N-domain
ACE isoform was solely found in the urine of hypertensive
humans and rats [15–22]. According to these studies, the
90kDa N-domain ACE was suggested as a genetic marker
of hypertension [21]. These described N-domain enzymes
are homologous isoforms to the N-terminal portion of the
somatic ACE [19]. They are expressed in many diﬀerent rat
tissues and in mesangial cells of Wistar and Spontaneously
Hypertensive Rats (SHRs) [19, 22–24] suggesting that these
enzymes may inﬂuence the local production of AngII and
modulate angiotensin (1–7) (Ang1–7) levels [19, 23, 24].
Thusfar,determinantsofRASactivityarenotcompletely
known and it may play an important role in the patho-
genesis of essential hypertension. Recently we described
the association of 90kDa N-domain ACE with plasma
inﬂammatory markers, endothelial function, and family
history of hypertension. Our data suggested that the 90kDa
ACE may be a marker for hypertension [25, 26]. Therefore,
the aim of this study was to investigate the presence of the
urinary 90kDa N-domain ACE in a large cohort of the
general population and to determine its association with
presenceofhypertensionandwithassociatedfactorsthatcan
contribute to development of high blood pressure.
2. Methods
A cross-sectional study of cardiovascular risk factors was
performed in the urban population of Vitoria, a city
southeast region of Brazil, following the general guidelines
of WHO-MONICA Project [27, 28]. A random sample of
1,661 households attended to the University Hospital to be
submitted to clinical and laboratory exams to determine the
cardiovascular risk proﬁle. Subjects (age 25–64 years) were
initially interviewed at their domiciles and then scheduled to
a visit to the University Hospital where they were submitted
to clinical and laboratory exams necessary to determine
the cardiovascular risk. Details of recruitment and sample
representation in the general population were described
elsewhere [29].
Subjects attended the University Hospital in 12h fasting
to blood sample collection and further evaluation of height,
weight, smoking habits, blood pressure, electrocardiogram,
aortic pulse wave velocity, and use of antihypertensive drugs.
Fasting glucose, cholesterol, triglycerides, and uric acid were
determined by standard techniques in a central laboratory.
Diabetes mellitus was deﬁned as fasting glucose >125mg/dL.
During the domicile visit all individuals were orientated to
collect all urine produced from 7pm to 7am to estimate
electrolyte(Na,K)andcreatininenocturnal12hexcretion.A
sampleofthisurinewasstoredat −20◦Candsenttoacentral
laboratory to determine presence of ACE isoforms.
Blood pressure (BP) was determined by trained nurses
using standard mercury sphygmomanometer on the left arm
after5minrestwiththesubjectinthesittingpositioninthree
diﬀerent times. The ﬁrst and ﬁfth phases of Korotkoﬀ sounds
were used for systolic and diastolic pressure, respectively.
Clinic BP was determined as the mean value of two record-
ings obtained with a minimum 10min interval. Presence of
hypertensionwasdeﬁnedaspresenceofclinicbloodpressure
≥140/90mmHg or use of antihypertensive drugs, including
diuretics [30].
This study was conducted in accordance with the Guide-
lines for Good Clinical Practice and the Declaration of
Helsinki after approval by the Ethics Committees on Human
Research from the Federal University of Esp´ ırito Santo
(volume 4194/99-00) and from Federal University of Sao
Paulo (0220/04). The informed consent was signed by all
volunteers.
2.1. Urine Preparation and Western Blotting Analysis. Urine
samples were collected with the addition of proteases
inhibitors (complete TM, mini EDTA-free, Roche) and
subsequent frozen. After unfrozen, pH was corrected to 8.0
with 1mol/L TRIS buﬀer. These samples were centrifuged
2568×g and the supernatant was concentrated in Microcon
(Millipore,USA).Theproteinconcentrationwasdetermined
by the Bradford method [31] (Bio-Rad Protein Assay Kit,
Bio-Rad, USA) using bovine serum albumin as standard.
After that, electrophoresis was performed on a 7.5% of slab
gelinpresenceofSDSaccordingtotheLaemmlimethod[32]
using 10μg denatured and reduced protein. Electrotrans-
ference was performed for 50 minutes at constant voltage
(40V) using a nitrocellulose membrane (Hybond ECL, GE
Healthcare, Sweden). The membrane was incubated in a
5.0% nonfat dry milk blocking solution for 4 hours before
overnight incubation at room temperature (20◦C) with
monoclonal antibody 9B9 (Chemicon International, USA)
(diluted1:1000).Thesubsequentstepswereperformedwith
the streptavidin/phosphatase alkaline system (GE Health-
care, Sweden) and the bands were revealed using substrates
NBT/BCIP as recommended by the manufacturer (Bio-Rad,
USA). In addition, the same researcher, blinded to clinical
data, performed all western blotting of this survey.
2.2. DEAE-Cellulose Chromatography of Human Urine. To
exemplify the urine separation of ACE isoforms we used
a DEAE-cellulose chromatography procedure. The super-
natant (100mL) of dialyzed urine collected in presence of
protease inhibitors (complete TM, mini EDTA-free, Roche)
was chromatographed on a DEAE-cellulose cellex D column
(1.5 × 10cm) equilibrated with 20mM Tris/HCl buﬀer, pH
7.0. Elution was carried out with a linear gradient of 20mM
to 500mM Tris/HCl buﬀer, pH 7.0 at a ﬂow rate of 60mL/h,
the protein elution proﬁle was monitored by UV absorbance
at 280nm, and the fractions were assayed for ACE activityInternational Journal of Hypertension 3
against Z-Phenyl-L-Histidyl-L-Leucine (Z-Phe-His-Leu) as
substrate (Bachem Bioscience Inc) as described previously
[19, 33].
2.3. Statistical Analysis. To evaluate the association between
blood pressure levels, metabolic and anthropometric param-
eters, the study population was divided according to ACE
isoforms in urine as follows: ACE 65/90/190kDa, presence
of three ACE isoforms; ACE 90+ (65/90kDa), and ACE
90− (65/190kDa) based on the presence (+) or absence
(−) of the 90kDa N-domain ACE isoform. Based on our
previous studies that the ACE 90+ group may be associated
with higher BP levels [19], we established, prior to the data
analysis, this group as the reference one for the comparisons
with the other two groups. All continuous variables were
examined for normality with the Kolmogorov-Smirnov test.
The chi-square test was applied for the comparison of
proportions. Analysis of variance followed by the Tukey test
for pairwise comparisons was used to compare more than
two independent means of continuous variables. Correlation
between continuous variables was determined by Pearson’s
coeﬃcient. Analysis of covariance was used to compare the
mean values of blood pressure levels between ACE groups
adjusting for potential confounding variables. Values of
continuous variables are expressed as mean values ± SE.
Statistical signiﬁcance was set at P<0.05.
3. Results
3.1. ACE Isoforms and Activity Proﬁle. The study population
was stratiﬁed according to ACE isoforms and the mean
age of the overall population was 44 years, range 23–65
years. Proﬁle of ACE isoforms found by Western blotting
analysis using the antibody (9B9) is shown in Figure 1.
After the Western blotting analysis, the urine prepared as
described in Section 2 of three volunteers that presented
with the 65, 90, and 190kDa, 65 and 90kDa, and 65 and
190kDa ACE isoforms were submitted to a DEAE-cellulose
chromatography. Proﬁle of ACE isoforms in these three
subjects are shown in Figure 1. The proﬁle was obtained
for urine of human subjects as described previously by our
group [19, 25, 26].
3.1. Demographic, Anthropometric, and Clinical Characteris-
tics. Demographic, anthropometric, and clinical character-
istics of the sample stratiﬁed according to ACE isoforms are
shown in Tables 1 and 2. Gender and ethnic distributions
were signiﬁcant diﬀerent among the three ACE groups,
whereas the smoking status and the proportion of diabetics
were similar (Table 1). The anthropometric parameters, lipid
proﬁle, and serum levels of both uric acid and glucose were
signiﬁcantlygreaterintheACE90+ groupcomparedwiththe
ACE 90− and ACE 65/90/190 groups (Table 2). In addition,
individuals from the ACE 90+ group had higher urinary of
sodium excretion when compared with the other groups.
No diﬀerence was observed in potassium and creatinine
excretion (Table 2).
ThemeansystolicanddiastolicBPwashigherintheACE
90+ comparedtotheACE90− andtheACE65/90/190groups
(Table 2). Since the hypertension was diagnosed according
to presence of the blood pressure values higher than
140/90mmHg in the clinic blood pressure measurement or
the use of antihypertensive drugs, we also analyzed these
groups separately.
It was observed that 795 individuals presented with 65,
90, and 190kDa, 186 individuals presented with 65 and
90kDa, and 169 individuals presented with 65 and 190kDa
ACE isoforms in their urine (Figure 2).
For the entire cohort, signiﬁcant positive associations
were observed between blood pressure levels and age, BMI,
waist-to-hip ratio, total cholesterol, triglycerides, uric acid,
glucose, and urinary sodium excretion (Table 3). To establish
if these correlations were not merely casual, multiple regres-
sion analyses were carried out. In a model adjusting for age,
gender, race, BMI, waist-to-hip ratio, blood lipids, uric acid,
sodium excretion, and glucose as independent variables, this
analysis showed that age (β = 0.533; SE = 0.051; P<0.001),
BMI (β = 0.901; SE = 0.117; P<0.001), serum uric acid
(β = 1.513; SE = 0.377; P<0.001), urinary sodium excre-
tion (β = 0.024; SE = 0.008; P = 0.005), and glucose (β =
0.057; SE = 0.016; P = 0.008) were independent predictors
of systolic blood pressure in the entire sample. Similar
analysis was performed to diastolic blood pressure and we
found that age (β = 0.164; SE = 0.033; P<0.001), BMI (β =
0.685; SE = 0.077; P<0.001), waist-to-hip ratio (β =
20.054; SE = 5.257; P<0.001), uric acid (β = 0.706; SE =
0.446; P = 0.004), and urinary sodium excretion (β = 0.021;
SE = 0.005; P = 0.005) reached statistical signiﬁcance.
Because multifactorial events are involved in the patho-
genesis of hypertension, and high levels of blood pressure
were found in individuals from the ACE 90+group, we
performed an analysis of covariance controlling for potential
confounding variables such as age, gender, race, smoking
status, presence of diabetes, BMI, waist-to-hip ratio, anti-
hypertensive drugs use lipid proﬁle, glucose, uric acid and
urinary sodium excretion. After these adjustments, the mean
value for both diastolic and systolic blood pressure remained
higher in the ACE 90+ group than that in the ACE 90−
and in the ACE 65/90/190 groups, although there was a
attenuation in the blood pressure levels between groups
(Table 4) (Figures 3(a) and 3(b)).
4. Discussion
Diﬀerent components of the RAS have been implicated
in association with EH, a well-established cardiovascular
risk factor aﬀecting nearly 1 billion individuals worldwide
[6]. Many studies show that the RAS exerts an important
inﬂuence on water, sodium, and potassium homeostasis,
thus inﬂuencing blood pressure regulation. ACE activity
exertsakeyroleontheactivityoftheRASandbloodpressure
regulation because this enzyme modulates angiotensin gen-
erationaswellasbradykininbreakdown,apotentvasodilator
peptide. ACE activity varies according to its isoforms.
However, results of studies trying to associate functional4 International Journal of Hypertension
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Figure 1:ChromatographyofhumanurinefromnormalandhypertensivesubjectsonDEAE-cellulose.(a1)Normotensivesubjectswithtwo
peaks with ACE activity corresponding to 190 and 65kDa ACE; (b1) Hypertensive subjects with two peaks with ACE activity corresponding
to 90 and 65kDa ACE; (c1) Normotensive subjects with three peaks with ACE activity corresponding to 190, 90, and 65kDa ACE. The
dialyzed human urine (100mL) was applied to a DEAE-cellulose column (1.5 × 10cm). The column was washed with 20mM Tris/HCl
buﬀer, pH 7.0, and then eluted (fractions of 4.5mL) with a linear gradient of 20mM to 500mM Tris/HCl buﬀe r ,p H7 . 0 ,a taﬂ o wr a t eo f
55mL/h. (◦) Absorbance at 280nm. (•) ACE activity with HHL as substrate. () Conductivity. Werstern blotting analysis of urinary ACEs.
(a2) Normotensive subjects with 190 and 65kDa ACE; (b2) Hypertensive subjects with 90 and 65kDa ACE; (c2) Normotensive subjects with
190, 90, and 65kDa ACE (as described in Section 2).International Journal of Hypertension 5
Table 1: Demographic characteristics of the study population according to ACE isoforms.
Characteristics ACE 90+ ACE 65/90/190 ACE 90−
P value
N = 186 N = 795 N = 169
Gender (%)
Men 52 45 39 0.031
Women 48 55 61
Race (%)
White 34 33 37
Black or Mulatto 61 60 50 0.002
Others 5 7 13
Smoking status (%)
Yes 24 25 27 0.850
No
Diabetes mellitus (%)
Yes 13 9 7 0.103
No
Table 2: Anthropometric, clinical, and laboratory variables of the study population according to ACE isoforms.
Variables ACE 90+ ACE 65/90/190 ACE 90−
N = 186 N = 795 N = 169
Age (years) 48.5 ±0.7∗ 43.9 ±0.44 2 .7 ± 0.8
BMI (kg/m2)2 8 .2 ±0.4∗ 26.1 ±0.22 5 .2 ± 0.4
Waist-to-hip ratio 0.91 ±0.01∗ 0.87 ±0.03 0.85 ±0.07
SBP (mmHg) 145.6 ±1.4∗ 126.5 ±0.8 114.9 ±0.9
DBP (mmHg) 95.4 ±0.8∗ 83.7 ±0.57 5 .7 ± 0.6
Cholesterol (mg/dL) 230.3 ±3.6∗ 210.5 ±1.6 208.4 ±3.4
LDLc (mg/dL) 153.7 ±3.3# 139.3 ±1.5 140.4 ±2.9
HDLc (mg/dL) 45.8 ±1.04 5 .7 ±0.54 4 .8 ± 0.8
Triglycerides (mg/dL) 162.2 ±8.3∗ 134.4 ±4.4 114.5 ±7.1
Uric acid (mg/dL) 5.1 ±0.1# 4.7 ±0.14 .4 ±0.1
Glucose (mg/dL) 112.2 ±3.2# 104.3 ±1.1 100.6 ±2.1
Urinary creatinine (mg/12h) 700.0 ±27.9 690.4 ±12.6 683.2 ± 23.6
Urinary sodium (mEq/12h) 108.8 ±4.5# 97.8 ±2.09 0 .9 ± 3.9
Urinary potassium (mEq/12h) 25.8 ±1.52 3 .2 ±0.62 3 .0 ± 1.0
Values expressed as mean ± SE. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: Low-density-lipoprotein cholesterol;
HDL:High-density-lipoproteincholesterol. ∗P<0.001and #P<0.05forthecomparisonofACE90+ versus ACE 90− andACE90+ versusACE65/90/190kDa
groups.
Table 3: Pearson’s correlation coeﬃcient between blood pressure levels, anthropometric and clinical variables in the total sample.
SBP DBP Age BMI WHR Cholesterol Triglycerides Glucose Uric acid
DBP 0.803∗∗
Age 0.351∗ 0.237∗
BMI 0.320∗ 0.335∗ 0.154∗
WHR 0.362∗ 0.399∗ 0.352∗ 0.408
Cholesterol 0.187∗ 0.151∗ 0.304∗ 0.149∗ 0.137∗
Triglyceride 0.217∗ 0.262∗ 0.132∗ 0.202∗ 0.238∗ 0.347∗
Glucose 0.227∗ 0.145∗ 0.277∗ 0.251∗ 0.259∗ 0.215∗ 0.237∗
Uric acid 0.262∗ 0.288∗ 0.105 0.261∗ 0.396∗ 0.176∗ 0.342∗ 0.064
Sodium excretion 0.141∗ 0.204∗ 0.041 0.177∗ 0.265∗ 0.015 0.084 0.108 0.119∗
BMI: body mass index; WHR: Waist-to-hip Ratio; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure. ∗P<0.05 and ∗∗P ≤ 0.001.6 International Journal of Hypertension
Table 4: Systolic and diastolic blood pressure levels and ACE isoforms in adjusted covariance analysis.
Groups SBP (mmHg) DBP (mmHg)
ACE 90+ 138.4 (135.8 to 141.0)∗ 90.9 (89.2 to 92.6)∗
ACE 65/90/190 127.0 (125.8 to 128.3) 84.1 (83.2 to 84.9)
ACE 90− 119.3 (116.5 to 122.1) 78.5 (76.7 to 80.4)
Values expressed as mean (95% conﬁdence interval). SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure. SBP and DBP are adjusted for age, gender,
race, smoking status, diabetes incidence, antihypertensive drugs use, BMI, waist-to-hip ratio, lipid proﬁle, glucose, uric acid, and urinary sodium excretion.
∗P<0.001 for the comparison of ACE 90+ versus ACE 90− and ACE 90+ versus ACE 65/90/190kDa groups.
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Figure 2: Distribution of ACE urinary isoforms and percentile of
presence in subjects urine.
variants of the RAS with EH have been contradictory [34–
36].
These contradictory ﬁndings may be explained for the
majority of the studies by inadequate sample size leading to
reduced statistical power. It is important to note that in the
presentstudydatawerecollectedinalargeandrepresentative
sample of the general population [37, 38].
The sample studied had 1150 volunteers, 505 males and
645 females, 45.8 and 54.2%, respectively. According to the
Brazilian 2000 Census, these percentages are close to the
gender population distribution of Vitoria (46.2 and 53.8%)
[39].
Urinary analysis of ACE isoforms showed that 85.3%
of subjects present ACE 90kDa isoform while in 14.7% of
the subjects the 90kDa ACE isoform was absent. Subjects
presenting the three ACE isoforms 65/90/190kDa represent
the higher population subgroup (around 69.1%) and in
this group 38% were hypertensive. These data strongly
suggest that the presence of the 90kDa N-domain ACE
isoform in the urine could be associated with EH. These
data conﬁrm and extend previous studies of our laboratory
where we detected a positive association of urinary 90kDa
ACE isoform with family history of hypertension and
endothelial function in normotensive individuals [25]. We
also described a direct association of 90kDa N-domain ACE
with plasma inﬂammatory markers and endothelial function
[26]. A reduction in the basal NO production was suggested,
conﬁrmed by NO urine analysis in subjects with the 90kDa
N-domain ACE isoform alone or associated with a family
history of hypertension. These data suggest that presence
of the 90kDa N-domain ACE itself may have a negative
impact on ﬂow-mediated dilatation stimulated by reactive
hyperemia [26]. In addition, results of the studies of Ronchi
et al. [22, 24] and Marques et al. [21] using normotensive
and spontaneously hypertensive rats showed that this N-
domain isoform could also be a possible genetic marker of
hypertension.
The proteic proﬁle of ACE isoforms found in the urine
of volunteers repeated the previous results of our group
[16–19, 25, 26], showing though that 90kDa ACE isoform
was present in urine of hypertensive subjects (42%) and
was present in a very few percentage (1%) in urine of
normotensive subjects (without 90kDa ACE). The expres-
sion of the ACE with 90kDa was detected in the group
with the 65/90/190 ACE isoforms and in the group with
90 and 65kDa. ACE activity proﬁle using DEAE-cellulose
chromatography was the same previously described by our
group [19, 25, 26] for the aleatory samples analyzed.
We showed normotensive subjects with two peaks
with ACE activity corresponding to 190 and 65kDa ACE,
hypertensive subjects with two peaks with ACE activity
corresponding to 90 and 65kDa ACE, and normotensive
subjects with three peaks with ACE activity corresponding
to 190, 90 and 65kDa ACE. The analysis of expression by
Werstern blotting of urinary ACEs showed that the bands
corresponding to these peaks conﬁrm the proﬁle found in
the chromatography.
Statistical analysis showed a positive association between
90kDa N-domain ACE isoform and presence of hyperten-
sion. Since this ﬁnding was observed in a transversal study,
we cannot establish a casual relationship between these
variables. However we can speculate some casual relation
between presence of 90kDa isoform and age-dependent
blood pressure increase because blood pressure values were
quitelowintheACE90− groupandhypertensionwasalmost
absent.
Several studies have shown that acid uric plasma level
independently predicts hypertension development and can
even be causal [40, 41]. It is considered a durable marker of
risk for the development of EH [40]. We found a positive
correlation of uric acid levels with both SBP and DBP
through simple linear regression. To further evaluate the
clinical relevance of this ﬁnding we evaluated the relations
between these variables in the presence of risk factors.
Through multivariate linear regression adjusted for age,
gender, ethnicity, WHR, and lipid proﬁle the association
between both SBP and DBP with uric acid was still statisti-
callysigniﬁcant,whichevidencesthatthiscorrelationpersists
even adjusted for other important hypertension-associated
risk factors. These data are according to results of Teixeira
et al. [25]; they described that subjects who presented withInternational Journal of Hypertension 7
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Figure 3: (a) Systolic and (b) diastolic blood pressure levels before (solid symbol) and after (open symbol) adjustment for age, gender,
race, smoking status, diabetes incidence, antihypertensive use, BMI, waist-to-hip ratio, lipid proﬁle, glucose, uric acid, and urinary sodium
excretion. Values are mean ± SEM.
90kDa ACE had triglycerides levels higher than subjects
without this isoform.
In Pearsons’s analysis we observed a positive correlation
between age, BMI, WHR, cholesterol, triglyceride, glucose,
uric acid, sodium excretion, and either SBP and DBP. In
addition to covariance analysis in subjects with presence
or absence of the 90kDa N-domain ACE isoform, both
associations were sustained for both SBP and DBP in the
group with 90kDa N-domain ACE isoform present.
Despite the correlation described previously, the physio-
logical signiﬁcance of the 90kD ACE isoform remains to be
determined. It will be important to determine whether it is
a splicing variant, a posttranscription alteration product, or
simply produced by the degradation of the 190kDa isoform.
Independent of the mechanism for production of the soluble
form of N-domain ACE, this isoform may be physiologically
and pathophysiologically important [42–46].
Analysis of blood pressure levels could show that subjects
with 90kDa ACE have systolic and diastolic values higher
thanthegroupwithoutthisisoform.Whenthegroupwith90
and65isoformswasanalyzed,theyhavesystolicanddiastolic
levels higher than the other two groups (ACE 65/90/165 and
ACE 90−). As shown in Figure 3 we can see that the early
appearing of 90kDa isoform either with three isoforms or
withtwoisoformsseemstocontributetoincreaseofdiastolic
and systolic levels. This can suggest that 90kDa isoform can
be involved in the increase of blood pressure, since ACE
activity using speciﬁc substrates to N domain ACE isoform
as ZPhe-His Leu was higher in hypertensive subjects. Data
strongly suggest that normotensive subjects from group 1
(65,90,and190kDaACE isoforms)deservespecialattention
whenitcomestopreventionsince90kDaN-domainisoform
is positively associated with hypertension.
5. Conclusions
There is a high presence of the 90kDa N-domain ACE
isoform (85%) in the studied population. In addition this
enzyme is associated with many known risk factors for
cardiovascular disease. Although the mechanism involved
in the generation of this isoform remains unknown, some
physiological alterations can be associated with this expres-
sion in human urine and this should be used to assess
hypertension risk in normotensive individuals. However,
casual relationships should be established in longitudinal
studies.
A second phase (5 years after) of this study is already
being done prospectively analyzing ACE isoforms in the
urine of these same volunteers, so causal associations may
be evaluated. The percentile of normotensive subjects with
three isoform was 62%; a prospective study of these subjects,
specially, is very important to know how many will develop
hypertension once they express the possible biomarker of
hypertension (ACE 90kDa) in their urine and will be
possibleconﬁrmthatthisbiomarkercanreallypredicthyper-
tension.
Ourﬁndingscouldcontributetothedevelopmentofnew
eﬃcient strategy to prevent and treat hypertension to avoid
the development of cardiovascular disease.
The ACE 90kDa absent is clearly associated with many
important factors in maintenance of lower levels of blood
pressure as (low weight, low salt ingestion, and low glucose
tolerance) that increase with aging. These people can be
a low proinﬂammatory status (opposite the group with
the presence of the 90kDa) and with low predisposition
to increase of blood pressure levels. Finally the practical
consequence of this study is that the 90kDa ACE was
associated with the presence of hypertension and the absence
of this was associated with subjects with normal blood
pressure levels, so this isoform would be a urinary marker
of hypertension in normotensive subjects.
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